Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelop proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.
Abstract: The invention is an apparatus and method for performing the Western Blot Assay and other assays. The invention includes a tray within which multiple samples can be assayed with a minimum of operator attention. The tray that is desirably used with the apparatus is multichambered and can be alternately agitated and drained according to drive cards and/or other controls such as electronic controls. The tray is designed in such a way that reagents and washing fluids, which are added sequentially and then cleared, do not back flow into the chambers of the tray.
Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.
Abstract: The protease necessary for polyprotein processing in Hepatitis G virus (HGV) is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HGV.
Abstract: Peptide antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV derived peptides and in particular, SG3, are immunoreactive with sera from individuals infected with HEV. The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV.
Type:
Grant
Filed:
May 9, 1994
Date of Patent:
November 11, 1997
Assignee:
Genelabs Technologies, Inc.
Inventors:
Gregory R. Reyes, Albert W. Tam, Patrice O. Yarbough
Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.
Abstract: The invention is an apparatus and method for performing the Western Blot Assay and other assays. The invention includes a tray within which multiple samples can be assayed with a minimum of operator attention. The tray that is desirably used with the apparatus is multichambered and can be alternately agitated and drained according to drive cards and/or other controls such as electronic controls. The tray is designed in such a way that reagents and washing fluids, which are added sequentially and then cleared, do not back flow into the chambers of the tray.